02084nam a22002057a 4500 D0001J000020 DOH 20210211113836.0 210211b ||||| |||| 00| 0 eng d Cost-effectiveness analysis of imidapril compared to metoprolol in the treatment of stage 1 essential hypertension among Filipino patients seen at the Philippine General Hospital / He Wentian [two others] OBJECTIVE: To evaluate the cost-effectiveness of imidapril versus metoprolol as monotherapy in Filipino patients with Stage 1 essential hypertension. STUDY DESIGN: Cost-effectiveness analysis from the perspective of the health care payer. METHOD: Medical records of 94 out-patients aged 40-70 years old, with Stage 1 essential hypertension and follow-up treatment of 3 months at the Philippine General Hospital were reviewed. Effectiveness of each drug was based on: 1) percentage of patients achieving target blood pressure (< 140 / 90 mmHg); and 2) mean reduction of systolic and diastolic blood pressure. Cost-effectiveness of each drug was evaluated using the criteria of cost-effectiveness ratio (CER) and the incremental cost-effectiveness ratio (ICER). RESULTS: The mean cost of treatment with metoprolol was significantly lower than imidapril. However, treatment with imidapril resulted in a statistically significantly better blood pressure control compared to metoprolol; 77 percent of those given imidapril achieved the target BP vs 56 percent for metoprolol (p=0.03). CER and the ICER showed that 3-months treatment with metoprolol is more cost-effective than the use of imidapril. CONCLUSION: Use of metoprolol over a 3-month period is more cost-effective than imidapril in the treatment of Filipino patients with Stage 1 essential hypertension. In: Acta Medica Philippina, 2006 vol. 40 (1) pages: 29-36 Metoprolol Hypertension therapy Imidapril Wentian, He Jimeno, Cecilia A. Panelo, Carlo Irwin A. JA 2804 2804 0 0 nlm 0 0 DOHCL DOHCL ElectronicRes 2021-02-11 0 J000020 D0001J000020 2021-02-11 00:00:00 2021-02-11 JA